Name: 59377-19-4|4-Phenoxyphenylisocyanate|98%
Brand: Ambeed
SKU: A853414
Price: 13.0 USD
Availability: InStock
Rating: 99 (22 reviews)

1
[ 59377-19-4 ]
[ 23308-83-0 ]
2-(4-phenoxy-phenyl)-2H-indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
45%	With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile at 60℃;

Reference： [1]Taher; Ladwa; Rajan; Weaver [Tetrahedron Letters, 2000, vol. 41, # 50, p. 9893 - 9897]

2
[ 537-46-2 ]
[ 59377-19-4 ]
[ 353525-94-7 ]

Yield	Reaction Conditions	Operation in experiment
76%	In dichloromethane at 20℃; for 18h;

Reference： [1]Fotsch; Sonnenberg; Chen; Hale; Karbon; Norman [Journal of Medicinal Chemistry, 2001, vol. 44, # 14, p. 2344 - 2356]

3
[ 59377-19-4 ]
[ 101-40-6 ]
1-(2-cyclohexyl-1-methylethyl)-1-methyl-3-(4-phenoxyphenyl)urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane at 20℃; for 1h;

Reference： [1]Fotsch; Sonnenberg; Chen; Hale; Karbon; Norman [Journal of Medicinal Chemistry, 2001, vol. 44, # 14, p. 2344 - 2356]

4
[ 59377-19-4 ]
7-ethoxy-6-methoxy-4-piperazin-1-yl-quinazoline [ No CAS ]
4-(7-Ethoxy-6-methoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine In N,N-dimethyl-formamide at 20℃;
	With triethylamine

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]
[2]Matsuno, Kenji; Seishi, Takashi; Nakajima, Takao; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Oda, Shoji; Nomoto, Yuji [Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, # 18, p. 3001 - 3004]

5
[ 59377-19-4 ]
6-ethoxy-7-methoxy-4-piperazin-1-yl-quinazoline [ No CAS ]
4-(6-Ethoxy-7-methoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine In N,N-dimethyl-formamide at 20℃;
	With triethylamine

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]
[2]Matsuno, Kenji; Seishi, Takashi; Nakajima, Takao; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Oda, Shoji; Nomoto, Yuji [Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, # 18, p. 3001 - 3004]

6
[ 59377-19-4 ]
[ 57260-71-6 ]
[ 245449-93-8 ]

Yield	Reaction Conditions	Operation in experiment
80%	In dichloromethane at 20℃;
	In methanol; dichloromethane	R.1 4-[N-(4-Phenoxyphenyl)carbamoyl]-1-piperazinecarboxylic acid tert-butyl ester Reference Example 1 4-[N-(4-Phenoxyphenyl)carbamoyl]-1-piperazinecarboxylic acid tert-butyl ester To a methylene chloride solution (25 mL) of N-tert-butoxycarbonylpiperazine (2.50 g, 13.4 mmol), 4-phenoxyphenyl isocyanate (2.83 mL, 13.4 mmol) was added, followed by stirring at room temperature overnight. Methanol was added to the reaction solution, and the solvent was evaporated to give the target compound (5.71 g, 14.4 mmol). Yield: quantitative 1H-NMR (CDCl3) δ (ppm): 7.35-7.26 (4H, m), 7.07 (1H, m), 6.99-6.95 (4H, m), 6.35 (1H, brs), 3.49 (8H, m), 1.48 (9H, s). FAB-Mass: 398 ((M+1)+)

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]
[2]Current Patent Assignee: Kyowa Kirin (in: Kirin Holdings); KIRIN HOLDINGS CO., LTD. - US6423716, 2002, B1

7
[ 59377-19-4 ]
[ 126653-00-7 ]
4-(1-isoquinolyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine In N,N-dimethyl-formamide at 20℃;

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]

8
[ 59377-19-4 ]
[ 461429-70-9 ]
{4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-phenoxyphenyl)carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine In N,N-dimethyl-formamide at 20℃;

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]

9
[ 59377-19-4 ]
[ 223587-51-7 ]
4-(4-Chloro-1-phthalazinyl)-N-(4-Phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine In N,N-dimethyl-formamide at 20℃;

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]

10
[ 59377-19-4 ]
7-isopropoxy-6-methoxy-4-piperazin-1-yl-quinazoline [ No CAS ]
4-(7-Isopropoxy-6-methoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine In N,N-dimethyl-formamide at 20℃;

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]

11
[ 59377-19-4 ]
methanesulfonic acid 7-methoxy-4-piperazin-1-yl-quinazolin-6-yl ester [ No CAS ]
4-(6-Mesyloxy-7-methoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine In N,N-dimethyl-formamide at 20℃;

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]

12
[ 59377-19-4 ]
6,7-dimethoxy-4-piperazin-1-yl-quinoline-3-carboxylic acid ethyl ester [ No CAS ]
4-(6,7-Dimethoxy-3-ethoxycarbonyl-4-quinolyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine In N,N-dimethyl-formamide at 20℃;

Reference： [1]Matsuno, Kenji; Ushiki, Junko; Seishi, Takashi; Ichimura, Michio; Giese, Neill A.; Yu, Jin-Chen; Takahashi, Shusuke; Oda, Shoji; Nomoto, Yuji [Journal of Medicinal Chemistry, 2003, vol. 46, # 23, p. 4910 - 4925]

13
[ 7154-73-6 ]
[ 59377-19-4 ]
[ 53298-33-2 ]
(R)-3-benzylsulfanyl-2-[3-(4-phenoxy-phenyl)-ureido]-N-(2-pyrrolidin-1-yl-ethyl)-propionamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 4477 - 4492

14
[ 23159-07-1 ]
[ 59377-19-4 ]
[ 102410-65-1 ]
2-[3-(4-phenoxy-phenyl)-ureido]-2-phenyl-N-(3-pyrrolidin-1-yl-propyl)-acetamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 4477 - 4492

15
[ 23159-07-1 ]
[ 59377-19-4 ]
[ 169555-95-7 ]
2-[3-(4-phenoxy-phenyl)-ureido]-3-pyridin-4-yl-N-(3-pyrrolidin-1-yl-propyl)-propionamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 4477 - 4492

16
[ 3653-34-7 ]
[ 59377-19-4 ]
5-methyl-3-[3-(4-phenoxy-phenyl)-ureido]-hexanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 4493 - 4509

17
[ 59377-19-4 ]
(S)-2-amino-3-methyl-N-(2-pyrrolidin-1-yl-ethyl)-butyramide [ No CAS ]
(S)-3-methyl-2-[3-(4-phenoxy-phenyl)-ureido]-N-(2-pyrrolidin-1-yl-ethyl)-butyramide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
50%	In dichloromethane at 20℃;
50%	In dichloromethane at 20℃;	79.C C. (S)-3-Methvl-2-f3- (4-phenoxv-phenvl)-ureidol-N- (2-pyrrolidin-1-vl-ethvl)- butyramide. 4-Phenoxy-phenyl isocyanate (0.1 g, 0.47 mmol) was added to a solution of (S)-2-amino-3-methyl-N-(2-pyrrolidin-1-yl-ethyl)-butyramide (0.05 g, 0.23 mmol) in CH2CI2 (2.3 mL). The reaction mixture was stirred at rt overnight, after which EtOAc (10 mL) and H20 (10 mL) were added. The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (20 mL), and dried (MgS04). The solvent was removed. Purification of the residue by flash column chromatography [0-20% MeOH (1% NH40H)/CH2CI2] afforded 0.058 g (50%) of the desired product. MS (electrospray) : mass calculated for C24H32N403, 424.5 ; m/z found, 425.2 [M+H] H NMR (400 MHz, CD30D) : 8.71 (s, 1 H), 8.05 (t, J = 5. 6 Hz, 1 H), 7.43-7. 37 (m, 2H), 7.36-7. 31 (m, 2H), 7.06 (t, J = 7.4 Hz, 1 H), 6.95-6. 91 (m, 4H), 6.3 (d, J= 9.0 Hz, 1H), 3.33 (s, 6H), 3.27-3. 12 (m, 2H), 2.47-2. 38 (m, 5H), 1.99-1. 89 (m, 1 H), 1.7-1. 62 (m, 4H), 0.87 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H).

Reference： [1]Wolin, Ronald L.; Venkatesan, Hariharan; Tang, Liu; Santillán Jr., Alejandro; Barclay, Tristin; Wilson, Sandy; Lee, Doo Hyun; Lovenberg, Timothy W. [Bioorganic and Medicinal Chemistry, 2004, vol. 12, # 16, p. 4477 - 4492]
[2]Current Patent Assignee: JOHNSON & JOHNSON INC - WO2005/44810, 2005, A1 Location in patent: Page/Page column 110

18
[ 690265-60-2 ]
[ 59377-19-4 ]
N-(4-phenoxyphenyl)-N'-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	In tetrahydrofuran at 60℃;
79%	In tetrahydrofuran at 50℃; for 1h;
	In tetrahydrofuran at 50℃; for 1h;	24 N-(4-phenoxyphenyl)-N'-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]urea EXAMPLE 24 N-(4-phenoxyphenyl)-N'-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]urea A mixture of 2-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-5-ylamine (0.100 g, 0.434 mmol) and 4-phenoxyphenyl isocyanate (0.0917 g, 0.434 mmol) in 6 mL of THF was stirred at 50° C. for 1 hour, cooled to room temperature and concentrated under reduced pressure. The residue was triturated in diethyl ether and collected by filtration to provide the title compound. 1H NMR (300 MHz, DMSO-D6) δ ppm 1.63 (m, 4 H), 2.44 (m, J=6.44 Hz, 4 H), 2.86 (t, J=6.61 Hz, 2 H), 4.46 (t, J=6.78 Hz, 2 H), 6.97 (m, 4 H), 7.09 (m, 1 H), 7.35 (m, 3 H), 7.49 (m, 2 H), 7.59 (m, 1 H), 7.88 (m, 1 H), 7.96 (s, 1 H), 8.65 (m, 2 H); MS (ESI) m/z 442 [M+H]+.

In tetrahydrofuran at 50℃; for 1h;

24 Example 24; N-(4-phenoxyphenyl)-N'-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]urea; A mixture of 2-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-5-ylamine (0.100 g, 0.434 mmol) and 4-phenoxyphenyl isocyanate (0.0917 g, 0.434 mmol) in 6 mL of THF was stirred at 50° C. for 1 hour, cooled to room temperature and concentrated under reduced pressure. The residue was triturated in diethyl ether and collected by filtration to provide the title compound. 1H NMR (300 MHz, DMSO-D6) δ ppm 1.63 (m, 4H), 2.44 (m, J=6.44 Hz, 4H), 2.86 (t, J=6.61 Hz, 2H), 4.46 (t, J=6.78 Hz, 2H), 6.97 (m, 4H), 7.09 (m, 1H), 7.35 (m, 3H), 7.49 (m, 2H), 7.59 (m, 1H), 7.88 (m, 1H), 7.96 (s, 1H), 8.65 (m, 2H); MS (ESI) m/z 442 [M+H]+.

Reference： [1]Souers, Andrew J.; Gao, Ju; Wodka, Dariusz; Judd, Andrew S.; Mulhern, Mathew M.; Napier, James J.; Brune, Michael E.; Bush, Eugene N.; Brodjian, Sevan J.; Dayton, Brian D.; Shapiro, Robin; Hernandez, Lisa E.; Marsh, Kennan C.; Sham, Hing L.; Collins, Christine A.; Kym, Philip R. [Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 11, p. 2752 - 2757]
[2]Kym, Philip R.; Souers, Andrew J.; Campbell, Thomas J.; Lynch, John K.; Judd, Andrew S.; Iyengar, Rajesh; Vasudevan, Anil; Gao, Ju; Freeman, Jennifer C.; Wodka, Dariusz; Mulhern, Mathew; Zhao, Gang; Wagaw, Seble H.; Napier, James J.; Brodjian, Sevan; Dayton, Brian D.; Reilly, Regina M.; Segreti, Jason A.; Fryer, Ryan M.; Preusser, Lee C.; Reinhart, Glenn A.; Hernandez, Lisa; Marsh, Kennan C.; Sham, Hing L.; Collins, Christine A.; Polakowski, James S. [Journal of Medicinal Chemistry, 2006, vol. 49, # 7, p. 2339 - 2352]
[3]Current Patent Assignee: ABBOTT LABORATORIES INC - US2005/137243, 2005, A1 Location in patent: Page/Page column 30-31
[4]Current Patent Assignee: ABBVIE INC - US2005/277638, 2005, A1 Location in patent: Page/Page column 31

19
[ 690265-64-6 ]
[ 59377-19-4 ]
N-(4-phenoxyphenyl)-N'-[2-(2-pyrrolidin-1-ylethyl)-2H-indazol-5-yl]urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
51%	In tetrahydrofuran at 50℃; for 1h;
	In tetrahydrofuran at 50℃; for 1h;	11 A mixture of 2-(2-pyrrolidin-1-yl-ethyl)-2H-indazol-5-ylamine (0.100 g, 0.434 mmol), 4-phenoxyphenyl isocyanate (0.0917 g, 0.434 mmol) and 6 mL of THF was stirred at 50° C. for 1 hour. The mixture was cooled to room temperature and the solvents removed under vacuo. The resultant solid was triturated in ether and collected by filtration to provide the titled product. 1H NMR (300 MHz, DMSO-D6) δ ppm 1.66 (m, 4H), 2.50 (m, 4H), 2.96 (m, 2H), 4.48 (t, J=5.93 Hz, 2H), 6.97 (m, 4H), 7.11 (m, 2H), 7.36 (m, 2H), 7.50 (m, 3H), 7.88 (m, 1H), 8.26 (s, 1H), 8.54 (s, 1H), 8.64 (s, 1H); MS (DCI/NH3) m/z 441 [M+H]+.
	In tetrahydrofuran at 50℃; for 1h;	11 N-(4-phenoxyphenyl)-N'-[2-(2-pyrrolidin-1-ylethyl)-2H-indazol-5-yl]urea Example 11 N-(4-phenoxyphenyl)-N'-[2-(2-pyrrolidin-1-ylethyl)-2H-indazol-5-yl]urea A mixture of 2-(2-pyrrolidin-1-yl-ethyl)-2H-indazol-5-ylamine (0.100 g, 0.434 mmol), 4-phenoxyphenyl isocyanate (0.0917 g, 0.434 mmol) and 6 mL of THF was stirred at 50° C. for 1 hour. The mixture was cooled to room temperature and the solvents removed under vacuo. The resultant solid was triturated in ether and collected by filtration to provide the titled product. 1H NMR (300 MHz, DMSO-D6) δ ppm 1.66 (m, 4H), 2.50 (m, 4H), 2.96 (m, 2H), 4.48 (t, J=5.93 Hz, 2H), 6.97 (m, 4H), 7.11 (m, 2H), 7.36 (m, 2H), 7.50 (m, 3H), 7.88 (m, 1H), 8.26 (s, 1H), 8.54 (s, 1H), 8.64 (s, 1H); MS (DCI/NH3) m/z 441 [M+H]+.

Reference： [1]Kym, Philip R.; Souers, Andrew J.; Campbell, Thomas J.; Lynch, John K.; Judd, Andrew S.; Iyengar, Rajesh; Vasudevan, Anil; Gao, Ju; Freeman, Jennifer C.; Wodka, Dariusz; Mulhern, Mathew; Zhao, Gang; Wagaw, Seble H.; Napier, James J.; Brodjian, Sevan; Dayton, Brian D.; Reilly, Regina M.; Segreti, Jason A.; Fryer, Ryan M.; Preusser, Lee C.; Reinhart, Glenn A.; Hernandez, Lisa; Marsh, Kennan C.; Sham, Hing L.; Collins, Christine A.; Polakowski, James S. [Journal of Medicinal Chemistry, 2006, vol. 49, # 7, p. 2339 - 2352]
[2]Current Patent Assignee: ABBOTT LABORATORIES INC - US2005/137187, 2005, A1 Location in patent: Page/Page column 24
[3]Current Patent Assignee: ABBVIE INC - US2005/187279, 2005, A1 Location in patent: Page/Page column 25-26

20
[ 885672-69-5 ]
[ 59377-19-4 ]
1-[1-(4-chlorophenyl)-3-dimethylaminopropyl]-3-(4-phenoxyphenyl)-carbamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
75%	With triethylamine In tetrahydrofuran at 20℃; for 18h;

Reference： [1]Lehmann, Fredrik; Pettersen, Anna; Currier, Erika A.; Sherbukhin, Vladimir; Olsson, Roger; Hacksell, Uli; Luthman, Kristina [Journal of Medicinal Chemistry, 2006, vol. 49, # 7, p. 2232 - 2240]

21
[ 854935-98-1 ]
[ 59377-19-4 ]
[ 854935-99-2 ]

Yield	Reaction Conditions	Operation in experiment
1.10 g	In tetrahydrofuran at 60℃; for 1h;
	In tetrahydrofuran at 60℃; for 1h;	24C A mixture of 0.600 g of 24B (2.71 mmol) and 0.573 g of 4-phenoxyphenyl isocyanate in 36 mL of THF was heated to 60° C. for 1 hour. The mixture was cool to room temperature and concentrated under reduced pressure to provide a brown solid. The residue was triturated from boiling ether to provide 1.10 g of the title product. 1H NMR (300 MHz, DMSO-D6) δ ppm 3.29 (s, 6H), 4.48 (d, J=5.42 Hz, 2H), 4.86 (m, 1H), 6.96 (m, 4H), 7.12 (m, 2H), 7.35 (m, 2H), 7.51 (m, 3H), 7.88 (m, 1H), 8.21 (m, 1H), 8.57 (m, 1H), 8.66 (m, 1H); MS (ESI) m/z 433 [M+H]+.
	In tetrahydrofuran at 60℃; for 1h;	24.C N-[2-(2,2-dimethoxyethyl)-2H-indazol-5-yl]-N'-(4-phenoxyphenyl)urea Example 24C N-[2-(2,2-dimethoxyethyl)-2H-indazol-5-yl]-N'-(4-phenoxyphenyl)urea A mixture of 0.600 g of 24B (2.71 mmol) and 0.573 g of 4-phenoxyphenyl isocyanate in 36 mL of THF was heated to 60° C. for 1 hour. The mixture was cool to room temperature and concentrated under reduced pressure to provide a brown solid. The residue was triturated from boiling ether to provide 1.10 g of the title product. 1H NMR (300 MHz, DMSO-D6) δ ppm 3.29 (s, 6H), 4.48 (d, J=5.42 Hz, 2H), 4.86 (m, 1H), 6.96 (m, 4H), 7.12 (m, 2H), 7.35 (m, 2H), 7.51 (m, 3H), 7.88 (m, 1H), 8.21 (m, 1H), 8.57 (m, 1H), 8.66 (m, 1H); MS (ESI) m/z 433 [M+H]+.

Reference： [1]Kym, Philip R.; Souers, Andrew J.; Campbell, Thomas J.; Lynch, John K.; Judd, Andrew S.; Iyengar, Rajesh; Vasudevan, Anil; Gao, Ju; Freeman, Jennifer C.; Wodka, Dariusz; Mulhern, Mathew; Zhao, Gang; Wagaw, Seble H.; Napier, James J.; Brodjian, Sevan; Dayton, Brian D.; Reilly, Regina M.; Segreti, Jason A.; Fryer, Ryan M.; Preusser, Lee C.; Reinhart, Glenn A.; Hernandez, Lisa; Marsh, Kennan C.; Sham, Hing L.; Collins, Christine A.; Polakowski, James S. [Journal of Medicinal Chemistry, 2006, vol. 49, # 7, p. 2339 - 2352]
[2]Current Patent Assignee: ABBOTT LABORATORIES INC - US2005/137187, 2005, A1 Location in patent: Page/Page column 26
[3]Current Patent Assignee: ABBVIE INC - US2005/187279, 2005, A1 Location in patent: Page/Page column 27-28

22
[ 16254-21-0 ]
[ 59377-19-4 ]
N-[1-(4-chlorophenyl)-3-dimethylaminopropyloxycarbonyl]-4-phenoxyphenyl-amine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
64%	With triethylamine In tetrahydrofuran at 20℃; for 18h;

Reference： [1]Lehmann, Fredrik; Pettersen, Anna; Currier, Erika A.; Sherbukhin, Vladimir; Olsson, Roger; Hacksell, Uli; Luthman, Kristina [Journal of Medicinal Chemistry, 2006, vol. 49, # 7, p. 2232 - 2240]

23
[ 617244-32-3 ]
[ 59377-19-4 ]
[ 617244-39-0 ]

Yield	Reaction Conditions	Operation in experiment
42%	Stage #1: 4-amino-N-(2-dimethylamino-ethyl)-2-methoxy-benzamide; p-phenoxyphenylisocyanate In dichloromethane at 20℃; for 2h; Stage #2: With PS-Trisamine In dichloromethane	8 Example 8N- (2-Dimethylamino-ethyl)-2-methoxy-4- [3- (4-phenoxy-phenyl)-ureido]-benzamide To a solution of Ex 1 (30 mg, 0.13 mmol) in dichloromethane (2 jus) under nitrogen atmosphere was 4-phenoxyphenylisocyanate (64, ul, 0.30 mmol) added. The reaction was stirred for 2 h at room temperature, whereupon PS-trisamine (100 mg, 4.2 mmol/g). The suspension was gentle stirred over night. Methanol (20 pL) was added to dissolve some precipitation before the resin was filtered off and rinsed with dichloromethane (10, ut). The solvents were removed in vacuo and the crude product was purified through chromatography (silica, dichloromethane/methanol/ammonia, 100: 20: 2) giving 24 mg (42%) of the title compound. 1H NMR (300 MHz, CDCI3) : 6 2.53 (t, 2H), 3.54 (m, 2H), 3.90 (s, 3H), 8.52 (s, 1H), 8.67 (s, 1H)
	Stage #1: 4-amino-N-(2-dimethylamino-ethyl)-2-methoxy-benzamide; p-phenoxyphenylisocyanate In dichloromethane at 20℃; for 2h; Stage #2: With PS-Trisamine In dichloromethane	113 Example 113; N- (2-DIMETHYLAMINO-ETHYL)-2-METHOXY-4- [3- (4-PHENOXY-PHENYL)-UREIDO]-BENZAMIDE To a solution of Ex 1 (30 mg, 0.13 MMOL) in DICHLOROMETHANE (2 1L) under nitrogen atmosphere was 4-phenoxyphenylisocyanate (64 µl, 0.30 MMOL) added. The reaction was stirred for 2 h at room temperature, whereupon PS-trisamine (100 mg, 4.2 mmol/g). The suspension was gentle stirred over night. Methanol (20 pL) was added to dissolve some precipitation before the resin was filtered off and rinsed with DICHLOROMETHANE (10 ILL). The solvents were removed in vacuo and the crude product was purified through chromatography (silica, dichloromethane/methanol/ammonia, 100: 20: 2) giving 24 mg (42%) of the title compound.'H NMR (300 MHz, CDCl3) : 5 2.53 (t, 2H), 3.54 (m, 2H), 3.90 (s, 3H), 8.52 (s, 1H), 8.67 (s, 1H).

Reference： [1]Current Patent Assignee: 7TM PHARMA AS - WO2003/87045, 2003, A1 Location in patent: Page/Page column 49-50
[2]Current Patent Assignee: 7TM PHARMA AS - WO2004/48319, 2004, A1 Location in patent: Page 71

24
[ 777863-87-3 ]
[ 59377-19-4 ]
[ 777863-94-2 ]

Yield	Reaction Conditions	Operation in experiment
99%	In tetrahydrofuran for 12h;	4.A Example 4A, 3-{4-[1-[1-(4-tert-Butyl-cyclohexyl)-3-(4-phenoxy-phenyl)-ureidol-2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-benzoylamino}-propionic acid ethyl ester Example 4A 3-{4-[1-[1-(4-tert-Butyl-cyclohexyl)-3-(4-phenoxy-phenyl)-ureidol-2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-benzoylamino}-propionic acid ethyl ester The product from Example 2E (0.125 g, 0.23 mmol) was dissolved in THF (1.5 mL) and added 4-phenoxyphenyl isocyanate (0.05 g, 0.23 mmol) and stirred for 12 hours. The solvent was evaporated under reduced pressure to provide the title compound as an oil (0.175 g, 99%).

Reference： [1]Current Patent Assignee: ABBOTT LABORATORIES INC - US2004/209928, 2004, A1 Location in patent: Page column 19

25
[ 59377-19-4 ]
[ 762286-24-8 ]
C₃₁H₃₇N₅O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 0℃; for 0.5h;	23A.2 STEP 23A-2 : Amine 23a from the previous step was dissolved in THF (25 mL, ) stirred in an ice-bath and basified with DIEA. 4-Phenoxyphenyl isocyanate (1.15 g, 5.45 mmol) was added with stirring for 30 min. Quenching employed MEOH addition (1 mL. ) Solvent was removed by evaporation, and the residue was purified by flash chromatograph which yielded protected amine 2b2. (1.5 g, LC-MS: 528. 2 MH+.)

Reference： [1]Current Patent Assignee: NEUROCRINE BIOSCIENCES INC - WO2004/81005, 2004, A1 Location in patent: Page 74

26
[ 59377-19-4 ]
[ 854921-72-5 ]
1-[1-(2-dimethylamino-ethyl)-1H-indazol-5-yl]-3-(4-phenoxy-phenyl)-urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran at 50℃; for 6h;	28 1-[1-(2-dimethylamino-ethyl)-1H-indazol-5-yl]-3-(4-phenoxy-phenyl)-urea EXAMPLE 28 1-[1-(2-dimethylamino-ethyl)-1H-indazol-5-yl]-3-(4-phenoxy-phenyl)-urea A mixture of 1-(2-dimethylamino-ethyl)-1H-indazol-5-ylamine (42 mg, 0.17 mmol), 4-phenoxyphenyl isocyanate (36 mg, 0.17 mmol) in 2 mL of THF was heated to 50° C. for 6 hours, cool to room temperature and concentrated under reduced pressure. The residue was dissolved in 1.5 mL of a 1:1 mixture of dimethyl sulfoxide/methanol and purified by preparative reverse-phase HPLC. 1H NMR (300 MHz, DMSO-d6) ppm 2.85 (s, 6H), 3.63 (t, J=6.40, 2H), 4.77 (t, J=6.40, 2H), 7.09 (m, 2H), 6.97 (m, 4H), 7.36 (m, 2H), 7.47 (m, 1H), 7.57 (m, 2H), 7.67 (m, 1H), 7.97 (s, 1H), 8.10 (s, 1H), 8.98 (s, 1H); MS (DCI/NH3) m/z 416 [M+H]+.
	In tetrahydrofuran at 50℃; for 6h;	28 Example 28; 1-[1-(2-dimethylamino-ethyl)-1H-indazol-5-yl]-3-(4-phenoxy-phenyl)-urea; A mixture of 1-(2-dimethylamino-ethyl)-1H-indazol-5-ylamine (42 mg, 0.17 mmol), 4-phenoxyphenyl isocyanate (36 mg, 0.17 mmol) in 2 mL of THF was heated to 50° C. for 6 hours, cool to room temperature and concentrated under reduced pressure. The residue was dissolved in 1.5 mL of a 1:1 mixture of dimethyl sulfoxide/methanol and purified by preparative reverse-phase HPLC. 1H NMR (300 MHz, DMSO-d6) ppm 2.85 (s, 6H), 3.63 (t, J=6.40, 2H), 4.77 (t, J=6.40, 2H), 7.09 (m, 2H), 6.97 (m, 4H), 7.36 (m, 2H), 7.47 (m, 1H), 7.57 (m, 2H), 7.67 (m, 1H), 7.97 (s, 1H), 8.10 (s, 1H), 8.98 (s, 1H); MS (DCI/NH3) m/z 416 [M+H]+.

Reference： [1]Current Patent Assignee: ABBOTT LABORATORIES INC - US2005/137243, 2005, A1 Location in patent: Page/Page column 32
[2]Current Patent Assignee: ABBVIE INC - US2005/277638, 2005, A1 Location in patent: Page/Page column 33

27
[ 59377-19-4 ]
[ 75782-77-3 ]
N-(5-tert-butyl-3-thienyl)-N'-(4-phenoxyphenyl)urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
88%	In N,N-dimethyl-formamide at 50 - 60℃;	C.C1a C. General Methods of Urea Formation; C1a. Reaction of a Heterocyclic Amine with an Isocyanate; N-(5-tert-Butyl-3-thienyl)-N'-(4-phenoxyphenyl)urea; To a solution of 5-tert-butyl-3-thiophene-ammonium chloride (prepared as described in Method A4b; 7.28 g, 46.9 mmol, 1.0 equiv) in anh DMF (80 mL) was added 4-phenoxyphenyl isocyanate (8.92 g, 42.21 mmol, 0.9 equiv) in one portion. The resulting solution was stirred at 50-60° C. overnight, then diluted with EtOAc (300 mL). The resulting solution was sequentially washed with H2O (200 mL), a 1 N HCl solution (50 mL) and a saturated NaCl solution (50 mL), dried (Na2SO4), and concentrated under reduced pressure. The resulting off-white solid was recrystallized (EtOAc/hexane) to give a white solid (13.7 g, 88%), which was contaminated with approximately 5% of bis(4-phenoxyphenyl)urea. A portion of this material (4.67 g) was purified by flash chromatography (9% EtOAc/27% CH2Cl2/64% cyclohexane) to afforded the desired product as a white solid (3.17 g).
	In N,N-dimethyl-formamide at 50 - 60℃;	C1a N-(5-tert-Butyl-3-thienyl)-N'-(4-phenoxyphenyl)urea: To a solution of 5-tert-butyl-3-thiophene-ammonium chloride (prepared as described in Method A4b; 7.28 g, 46.9 mmol, 1.0 equiv) in anh DMF (80 mL) was added 4-phenoxyphenyl isocyanate (8.92 g, 42.21 mmol, 0.9 equiv) in one portion. The resulting solution was stirred at 50-60° C. overnight, then diluted with EtOAc (300 mL). The resulting solution was sequentially washed with H2O (200 mL), a 1 N HCl solution (50 mL) and a saturated NaCl solution (50 mL), dried (Na2SO4), and concentrated under reduced pressure. The resulting off-white solid was recrystallized (EtOAc/hexane) to give a white solid (13.7 g, 88%), which was contaminated with approximately 5% of bis(4-phenoxyphenyl)urea. A portion of this material (4.67 g) was purified by flash chromatography (9% EtOAc/27% CH2Cl2/64% cyclohexane) to afforded the desired product as a white solid (3.17 g).
	In DMF (N,N-dimethyl-formamide) at 50 - 60℃;	C.C1a To a solution of 5-tert-butyl-3-thiophene-ammonium chloride (prepared as described in Method A4b; 7.28 g, 46.9 mmol, 1.0 equiv) in anh DMF (80 mL) was added 4-phenoxyphenyl isocyanate (8.92 g, 42.21 mmol, 0.9 equiv) in one portion. The resulting solution was stirred at 50-60 °C overnight, then diluted with EtOAc (300 mL). The resulting solution was sequentially washed with H2O (200 mL), a 1 N HCl solution (50 mL) and a saturated NaCl solution (50 mL), dried (Na2SO4), and concentrated under reduced pressure. The resulting off-white solid was recrystallized (EtOAc/hexane) to give a white solid (13.7 g, 88%), which was contaminated with approximately 5% of bis(4-phenoxyphenyl)urea. A portion of this material (4.67 g) was purified by flash chromatography (9% EtOAc/27% CH2Cl2/64% cyclohexane) to afforded the desired product as a white solid (3.17 g).

Reference： [1]Current Patent Assignee: BAYER AG - US2007/244120, 2007, A1 Location in patent: Page/Page column 24
[2]Current Patent Assignee: BAYER AG - US2012/46290, 2012, A1 Location in patent: Page/Page column 24
[3]Current Patent Assignee: BAYER AG - EP1047418, 2005, B1 Location in patent: Page/Page column 39

28
[ 59669-59-9 ]
[ 59377-19-4 ]
N-(3-tert-butyl-5-isoxazolyl)-N'-(4-phenoxyphenyl)urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
70%	In dichloromethane; for 48h;Heating / reflux;	C1b. Reaction of a Heterocyclic Amine with an Isocyanate; N-(3-tert-Butyl-5-isoxazolyl)-N'-(4-phenoxyphenyl)urea; To a solution of <strong>[59669-59-9]5-amino-3-tert-butylisoxazole</strong> (8.93 g, 63.7 mmol, 1 eq.) in CH2Cl2 (60 mL) was added 4-phenyloxyphenyl isocyanate (15.47 g, 73.3 mmol, 1.15 eq.) dropwise. The mixture was heated at the reflux temp. for 2 days, eventually adding additional CH2Cl2 (80 mL). The resulting mixture was poured into water (500 mL) and extracted with Et2O (3.x.200 mL). The organic layer was dried (MgSO4) then concentrated under reduced pressure. The residue was recrystallized (EtOAc) to give the desired product (15.7 g, 70percent): mp 182-184° C.; TLC (5percent acetone/95percent acetone) Rf 0.27; 1H-NMR (DMSO-d6) delta 1.23 (s, 9H), 6.02 (s, 1H), 6.97 (dd, J=0.2, 8.8 Hz, 2H), 6.93 (d, J=8.8 Hz, 2H), 7.08 (t, J=7.4 Hz, 1H), 7.34 (m, 2H), 7.45 (dd, J=2.2, 6.6 Hz, 2H), 8.80 (s, 1H), 10.04 (s, 1H); FAB-MS m/z (rel abundance) 352 ((M+H)+, 70percent).
70%	In dichloromethane; for 48h;Reflux;	N-(3-tert-Butyl-5-isoxazolyl)-N'-(4-phenoxyphenyl)urea: To a solution of <strong>[59669-59-9]5-amino-3-tert-butylisoxazole</strong> (8.93 g, 63.7 mmol, 1 eq.) in CH2Cl2 (60 mL) was added 4-phenyloxyphenyl isocyanate (15.47 g, 73.3 mmol, 1.15 eq.) dropwise. The mixture was heated at the reflux temp. for 2 days, eventually adding additional CH2Cl2 (80 mL). The resulting mixture was poured into water (500 mL) and extracted with Et2O (3.x.200 mL). The organic layer was dried (MgSO4) then concentrated under reduced pressure. The residue was recrystallized (EtOAc) to give the desired product (15.7 g, 70percent): mp 182-184° C.; TLC (5percent acetone/95percent acetone) Rf 0.27; 1H-NMR (DMSO-d6) delta 1.23 (s, 9H), 6.02 (s, 1H), 6.97 (dd, J=0.2, 8.8 Hz, 2H), 6.93 (d, J=8.8 Hz, 2H), 7.08 (t, J=7.4 Hz, 1H), 7.34 (m, 2H), 7.45 (dd, J=2.2, 6.6 Hz, 2H), 8.80 (s, 1H), 10.04 (s, 1H); FAB-MS m/z (rel abundance) 352 ((M+H)+, 70percent).
70%	In dichloromethane; for 48h;Heating / reflux;	To a solution of <strong>[59669-59-9]5-amino-3-tert-butylisoxazole</strong> (8.93 g, 63.7 mmol, 1 eq.) in CH2Cl2 (60 mL) was added 4-phenyloxyphenyl isocyanate (15.47 g, 73.3 mmol, 1.15 eq.) dropwise. The mixture was heated at the reflux temp. for 2 days, eventually adding additional CH2Cl2 (80 mL). The resulting mixture was poured into water (500 mL) and extracted with Et2O (3 x 200 mL). The organic layer was dried (MgSO4) then concentrated under reduced pressure. The residue was recrystallized (EtOAc) to give the desired product (15.7 g, 70percent): mp 182-184 °C; TLC (5percent acetone/95percent acetone) Rf 0.27; 1H-NMR (DMSO-d6) delta 1.23 (s, 9H), 6.02 (s, 1H), 6.97 (dd, J=0.2, 8.8 Hz, 2H), 6.93 (d, J=8.8 Hz, 2H), 7.08 (t, J=7.4 Hz, 1H), 7.34 (m, 2H), 7.45 (dd, J=2.2, 6.6 Hz, 2H), 8.80 (s, 1H), 10.04 (s, 1H); FAB-MS m/z (rel abundance) 352 ((M+H)+,70percent).

Reference： [1]Patent: US2007/244120,2007,A1 .Location in patent: Page/Page column 24-25
[2]Patent: US2012/46290,2012,A1 .Location in patent: Page/Page column 24
[3]Patent: EP1047418,2005,B1 .Location in patent: Page/Page column 39-40

29
[ 863783-39-5 ]
[ 59377-19-4 ]
(2S,3S)-5-(3-hexyl-4-oxo-oxetan-2-yl)-pentyl-(4-phenoxyphenyl)-carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: (S,S)-4-(5-hydroxypentyl)-3-hexyl-oxetan-2-one; p-phenoxyphenylisocyanate In dichloromethane at 0 - 20℃; for 2.25h; Stage #2: With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 48h;	6.G A solution of 0.6 g (S,S)-4-[5-hydroxypentyl]-3-hexyl-oxetan-2-one in 10 ml dichloromethane was added dropwise to a solution of 0.78 g 4-phenoxyphenyl isocyanate in 10 ml dichloromethane at 0° C. under a nitrogen atmosphere. The mixture was then stirred for 15 minutes at 0° C. and then for 2 hours at RT. 0.43 ml diisopropylethylamine was added and the mixture was stirred for 2 days at RT. Then it was taken up with dichloromethane, the organic phase was washed in succession with water and saturated aqueous common salt solution, dried over sodium sulfate and evaporated in a vacuum. The remaining residue was flash-chromatographed with a solvent system consisting of n-hexane/ethyl acetate (4:1 v/v) on silica gel. Drying of the product fractions yielded 0.74 g of the title compound, m.p. 73-74° C.; [α]D=-21.5° (c=1 in EA); 1H-NMR (400 MHz, CDCl3): δ=0.89 (t, 3H), 1.2-1.9 (m, 18H), 3.18 (m, 1H), 4.17 (t, 2H), 4.22 (m, 1H), 6.55 (s, br, 1H), 6.96-7.00 (m, 4H), 7.07 ("t", 1H), 7.28-7.37 (m, 4H).

Reference： [1]Current Patent Assignee: ABBVIE INC - US2005/197386, 2005, A1 Location in patent: Page/Page column 13-14

30
trans-3-hexyl-4-(5-hydroxypentyl)-oxetan-2-one [ No CAS ]
[ 59377-19-4 ]
trans-(3-hexyl-4-oxo-oxetan-2-yl)-pentyl-(phenoxyphenyl)-carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: trans-3-hexyl-4-(5-hydroxypentyl)-oxetan-2-one; p-phenoxyphenylisocyanate In dichloromethane at 0 - 20℃; for 2.08333h; Stage #2: With N-ethyl-N,N-diisopropylamine	1.H trans-(3-hexyl-4-oxo-oxetan-2-yl)-pentyl-(phenoxyphenyl)-carbamate A solution of 5.5 g 3-hexyl-4-(5-hydroxypentyl)-oxetan-2-one in 25 ml dichloromethane was added dropwise under a nitrogen atmosphere to a solution of 5.8 g 4-phenoxyphenyl isocyanate in 50 ml dichloromethane at 0° C. and was left for 5 minutes at 0° C. Then it was stirred for 2 hours at RT and 0.4 ml diisopropylethylamine (="Hünig's base") was additionally added to complete the reaction. After stirring overnight, the reaction mixture was washed first with water, then with saturated aqueous common salt solution. Then the organic phase was dried over sodium sulfate and evaporated in a vacuum. The remaining residue was flash-chromatographed on silica gel, with initially pure n-hexane, to which a continuously increasing proportion of ethyl acetate was added, being used as mobile solvent. After evaporating the product fractions in a vacuum, a solid residue was obtained which was recrystallized from n-hexane/EA. 7.1 g of the title compound was obtained as pure trans product, mp. 63.1-66.3° C.; 1H-NMR (400 MHz, CDCl3): δ=0.89 (t, 3H), 1.2-1.9 (m, 18H), 3.17 (m, 1H), 4.17 (t, 2H), 4.22 (m, 1H), 6.55 (s, br, 1H), 6.96-7.00 (m, 4H), 7.07 (dt, 1H), 7.28-7.37 (m, 4H).

Reference： [1]Current Patent Assignee: ABBVIE INC - US2005/197386, 2005, A1 Location in patent: Page/Page column 9

31
[ 2486-80-8 ]
[ 59377-19-4 ]
[ 617244-40-3 ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane at 20℃; for 72h;	9 Example 9 2-Methoxy-4- [3- (4-phenoxy-phenyl)-ureido]-benzoic acid To a solution of 4-nitro-2-methoxybenzoic acid (5. 0g, mmol) in ethanol (100 pL) was added Pd/C (200 mg, 20% w/w). The reaction mixture was stirred at room temperature under a hydrogen atmosphere over night. The catalyst was filtered off through a pad of celite and the filtrate was concentrated in vacuo giving 4-amino-2-methoxybenzoic acid. To a solution of 4-amino-2-methoxybenzoic acid (0.50 g, 3.0 mmol) in dichloromethane (10 jj. L) was added 4-phenoxyphenylisocyanate (0.65 µL, 3.6 mmol) under inert atmosphere. The reaction mixture was stirred for three days at room temperature and a precipitate was formed. Filtration gave 1.1 g (97%) of the title compound.'H NMR (300 MHz, CDCI3) : 6 3.79 (s, 3H), 6.92-7. 02 (m, 5H), 7.09 (t, 1 H), 7.32-7. 42 (m, 3H), 7.48 (d, 2H), 7.66 (d, 1 H), 8.79 (s, 1 H), and 9.03 (s, 1 H).

Reference： [1]Current Patent Assignee: 7TM PHARMA AS - WO2003/87045, 2003, A1 Location in patent: Page/Page column 50

32
[ 331754-31-5 ]
[ 59377-19-4 ]
1-(6-dimethylaminomethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-3-(4-phenoxy-phenyl)-urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
89%	With PS-Trisamine In dichloromethane	4 1- (6-Dimethylaminomethyl-5, 6,7, 8-tetrahydro-naphthalen-2-yl)-3- (4-phenoxy- phenyl)-urea To a solution of the compound of Ex 3 (0.020 g, 0.098 mmol) in dry dichloromethane (2 ml) was added, under an argon atmosphere, 4-phenoxyphenylisocyanate (0.020 mi, 0.117 mmol). After stirring for 2 hours, PS-trisamine (0.029 mg, 3.38 mmol/g, 0.098 mmol) was added and the reaction mixture was stirred overnight, leading to the formation of a white precipitate. Methanol was added to dissolve the precipitate. PS-trisamine was filtered off and washed with dichloromethane. The filtrate was concentrated in vacuo to yield the title compound Ex 4 as a white solid (0.036 g, 0.087 mmol, 89%).'H NMR (300 MHz, DMSO- D6) : 8 2.14 (s, 6H), 6.80-7. 50 (m, 12H), 8.44 (s, 1H), 8.60 (s, 1H) ; Melting point: 185- 186. 5°C (uncorrected).

Reference： [1]Current Patent Assignee: 7TM PHARMA AS - WO2003/87046, 2003, A1 Location in patent: Page/Page column 42-43

33
[ 59377-19-4 ]
[ 150-13-0 ]
[ 617246-48-7 ]

Yield	Reaction Conditions	Operation in experiment
79%	In dichloromethane at 20℃; for 72h;	1 To a suspension of 4-aminobenzoic acid (430 mg, 3.13 mmol) in DCM (10 ml) under nitrogen atmosphere was added dropwise 4-phenoxyphenyl isocyanate (0.70 mi, 3.8 mmol). The reaction was stirred at room temperature for 3 days. The precipitate was filtered off and washed with DCM to give 866 mg (79%) of a white solid.'H NMR (300 MHz, DMSO-d6) 6 12.58 (s, 1 H), 9.03 (s, 1 H), 8.80 (s, 1 H), 7.87 (d, J = 8.5, 1 H).

Reference： [1]Current Patent Assignee: 7TM PHARMA AS - WO2003/87044, 2003, A2 Location in patent: Page/Page column 38

34
4-amino-N-(2-diethylamino-ethyl)-2-ethoxy-benzamide [ No CAS ]
[ 59377-19-4 ]
N-(2-diethylamino-ethyl)-2-ethoxy-4-[3-(4-phenoxy-phenyl)-ureido]-benzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
57%	Stage #1: 4-amino-N-(2-diethylamino-ethyl)-2-ethoxy-benzamide; p-phenoxyphenylisocyanate In dichloromethane at 20℃; Stage #2: With PS-Trisamine In dichloromethane for 18h;	133 A solution of 4-Amino-N-(2-diethylamino-ethyl)-2-ethoxy-benzamide (0. 08g, 0.286 mmol) and 4-phenoxyphenyl isocyanate (77. 6, ut, 0.429 mmol) in dichloromethane (5 ml) was stirred at RT overnight under an argon atmosphere. PS-trisamine (0.286 mmol) was added and the reaction mixture was stirred for a further 18h00. Methanol (1 ml) was added to dissolve the precipitate. The resin was filtered off and the filtrate was concentrated to give a semi-solid which was triturated with methanol. The solid was filtered, washed with methanol and dried in vacuo to give a white powder (0.08 g, 0.163 mmol, 57%). 1H NMR (300 MHz, DMSO): 8 0.97 (t, 6H), 1.45 (t, 3H), 2.53 (m, 6H), 3.35 (q, 2H), 4.18 (q, 2H), 6.95-7. 5 (m, 11H), 7.85 (d, 1H), 8. 2 (bm, 1H), 8.76 (s, 1H), 8.94 (s, 1H)

Reference： [1]Current Patent Assignee: 7TM PHARMA AS - WO2003/87045, 2003, A1 Location in patent: Page/Page column 92

35
[ 331759-01-4 ]
[ 59377-19-4 ]
1-(6-morpholine-4-ylmethyl-5,6,7,8-tetrahydro-naphthalene-2-yl)-3-(4-phenoxy-phenyl)-urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
22%	In dichloromethane at 20℃; for 16h;	25 1- (6-Morpholin-4-ylmethyl-5, 6,7, 8-tetrahydro-naphthalen-2-yi)-3- (4-phenoxy-phenyl)- urea To a solution of Ex20 (15 mg, 0.06 mmol) in dichloromethane (1 mL) stirred at ambient temperature under argon atmosphere was added 4-phenoxyphenylisocyanate (19 mg, 0.09 mmol). Stirring was continued for 16h before the product was isolated by direct addition of the reaction mixture to SCX column. Impurities were removed by elution with methanol (20 mL) before the elution of product urea with 5% ammonia in methanol (10 mL). Removal of volatiles in vacuo to give title compound Ex 25 (6 mg, 22%).'H NMR (CDCI3) â : 7.38-7. 24 (6H, m), 7.12-6. 91 (8H, m), 6.70 (1 H, br s), 6.60 (1 H, br s), 6.76 (4H, m), 6.91-1. 30 (13H, m).

Reference： [1]Current Patent Assignee: 7TM PHARMA AS - WO2003/87046, 2003, A1 Location in patent: Page/Page column 50-51

36
[ 59377-19-4 ]
[ 245449-27-8 ]
[ 245449-97-2 ]
4-(1-Methyl-4-1H-pyrazolo[3,4-d]pyrimidinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
81%	In <i>N</i>-methyl-acetamide	13 4-(1-Methyl-4-1H-pyrazolo[3,4-d]pyrimidinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide (Compound 13) EXAMPLE 13 4-(1-Methyl-4-1H-pyrazolo[3,4-d]pyrimidinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide (Compound 13) To a dimethylformamide solution (10 mL) of 1-methyl-4-(1-piperazinyl)-1H-pyrazolo[3,4-d]pyrimidine (482 mg, 2.21 mmol) produced in Reference Example 5, 4-phenoxyphenyl isocyanate (0.47 mL, 2.23 mmol) was added, followed by stirring overnight at room temperature. The reaction solution was poured into water, and the precipitated crystals were recovered by filtration, washed with water, dried, and then purified by silica gel column chromatography to give the target compound (770 mg, 1.79 mmol) as colorless crystals. Yield: 81% Melting point: 155-156° C. 1H-NMR (CDCl3) δ (ppm): 8.39 (1H, s), 7.93 (1H, s), 7.35-7.25 (4H, m), 7.06 (1H, m), 6.97-6.93 (4H, m), 6.75 (1H, brs), 4.12-4.08 (4H, m), 4.03 (3H, s), 3.79-3.75 (4H, m). FAB-Mass: 430 ((M+1)+) IR (KBr tablet method) ν (cm-1): 1664, 1578, 1506,1489, 1416, 1342, 1292, 1230, 993, 924, 750.

Reference： [1]Current Patent Assignee: Kyowa Kirin (in: Kirin Holdings); KIRIN HOLDINGS CO., LTD. - US6423716, 2002, B1

37
[ 59377-19-4 ]
[ 205259-36-5 ]
4-(6,7-Difluoro-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
98%	With triethylamine; trifluoroacetic acid In <i>N</i>-methyl-acetamide; dichloromethane	(Compound 205) 4-(6,7-Difluoro-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide (Compound 205) To a solution of 446.7 mg (1.27 mmol) of 4-(6,7-difluoro-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester obtained in Reference Example 7 in 3 ml of dichloromethane was added 3 ml of trifluoroacetic acid under ice-cooling, followed by stirring at the same temperature for 4 hours. After the solvent was evaporated, the residue was subjected to azeotropic distillation with toluene twice, and the obtained residue was dissolved in 10 ml of dimethylformamide. To the resulting solution were added 0.89 ml (6.39 mmol) of triethylamine and 0.27 ml (1.28 mmol) of 4-phenoxyphenyl isocyanate, followed by overnight stirring at room temperature. The reaction mixture was poured into water and sodium chloride was added thereto. The precipitated crystals were collected by filtration, washed with water, and dried, followed by purification by silica gel chromatography to give the desired compound as colorless crystals. Yield: 98% m.p.: 177-178° C. 1H-NMR(CDCl3) δ (ppm): 8.74(1 H, s), 7.71-7.62(2 H, m), 7.36-7.26(4 H, m), 7.05(1 H, m), 6.98-6.94(4 H, m), 6.69(1 H, brs), 3.83-3.72(8 H, m). FAB-Mass: 462(M++1) IR(KBr) ν (cm -1): 1633, 1578, 1508, 1489, 1423, 1227.

Reference： [1]Current Patent Assignee: Kyowa Hakko Kogyo Co., Ltd. - US6169088, 2001, A

38
1-thieno[3,2-d]pyrimidin-4-yl-pyrrolidin-3-ylamine hydrochloride [ No CAS ]
[ 59377-19-4 ]
1-(4-Phenoxy-phenyl)-3-(1-thieno[3,2-d]pyrimidin-4-yl-pyrrolidin-3-yl)-urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h;	13.c c. 1-(4-Phenoxy-phenyl)-3-(1-thieno[3,2-d]pyrimidin-4-yl-pyrrolidin-3-yl)-urea To a solution of 1-Thieno[3,2-d]pyrimidin-4-yl-pyrrolidin-3-ylamine hydrochloride (21 mg, 0.082 mmol) and diisopropylethylamine (17.3 mg, 0.172 mmol) in CH2Cl2 (0.5 mL) was added 4-phenoxyphenyl isocyanate (21 mg, 0.99 mmol). The resulting solution was stirred at RT for 16 h, then poured into 1 M HCl (5 mL) and extracted with CH2Cl2 (10 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated, and purified by silica gel chromatography (2% MeOH/CH2CH2) to provide the title compound (17 mg) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.05 (d, 1H), 7.35-7.28 (m, 5H), 7.05 (m, 1H), 6.92 (m, 4H), 4.49 (m, 1H), 4.22-3.98 (m, 3H), 3.87 (m, 1H), 2.36 (m, 1H), 2.11 (m, 1H). LC/MS (ESI): calcd mass 431.1, found 432.1 (MH)+.
	With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h;	13.c To a solution of 1-Thieno[3,2-d]pyrimidin-4-yl-pyrrolidin-3-ylamine hydrochloride (21 mg, 0.082 mmol) and diisopropylethylamine (17.3 mg, 0.172 mmol) in CH2Cl2 (0.5 mL) was added 4-phenoxyphenyl isocyanate (21 mg, 0.99 mmol). The resulting solution was stirred at RT for 16 h, then poured into 1 M HCl (5 mL) and extracted with CH2Cl2 (10 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated, and purified by silica gel chromatography (2% MeOH/) to provide the title compound (17 mg) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.05 (d, 1H), 7.35-7.28 (m, 5H), 7.05 (m, 1H), 6.92 (m, 4H), 4.49 (m, 1H), 4.22-3.98 (m, 3H), 3.87 (m, 1H), 2.36 (m, 1H), 2.11 (m, 1H). LC/MS (ESI): calcd mass 431.1, found 432.1 (MH)+.

Reference： [1]Current Patent Assignee: JOHNSON & JOHNSON INC - US2006/281768, 2006, A1 Location in patent: Page/Page column 25
[2]Current Patent Assignee: JOHNSON & JOHNSON INC - US2006/281769, 2006, A1 Location in patent: Page/Page column 40

39
[ 916610-41-8 ]
[ 59377-19-4 ]
1-(4-Phenoxy-phenyl)-3-(1-thieno[3,2-d]pyrimidin-4-yl-piperidin-4-yl)-urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
70%	In dichloromethane at 20℃;	22 1-(4-Phenoxy-phenyl)-3-(1-thieno [3,2-d]pyrimidin-4-yl-piperidin-4-yl)-urea EXAMPLE 22 1-(4-Phenoxy-phenyl)-3-(1-thieno [3,2-d]pyrimidin-4-yl-piperidin-4-yl)-urea 4-Phenoxyphenyl isocyanate (35 mg, 170 μmol) was added to a solution of 1-thieno[3,2-d]pyrimidin-4-yl-piperidin-4-ylamine (35 mg, 150 μmol) (Example 20b) in DCM (300 μL). The solution was stirred at rt overnight, at which point it became a slurry. The reaction was then partitioned with DCM (2 mL) and 2.0M K2CO3 (2 mL), the aqueous layer was extracted with 9:1 DCM/MeOH (2*2 mL), and the combined organic layers were filtered. The clear filtrate was dried (Na2SO4), concentrated, and purified by C18 HPLC followed by a bicarbonate solid phase extraction cartridge to afford the title compound (46.6 mg, 70%). 1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 7.72 (d, 1H), 7.42 (d, 1H), 7.33 (m, 2H), 7.22 (m, 2H), 7.10 (m, 1H), 6.97 (m, 4H), 6.19 (br s, 1H), 4.76 (m, 2H), 4.54 (d, 1H), 4.08 (m, 1H), 3.30 (m, 2H), 2.16 (m, 2H), 1.45 (m, 2H). LC/MS (ESI): calcd mass 445.2, found 446.1 (MH)+.
70%	In dichloromethane at 20℃;	22 1-(4-Phenoxy-phenyl)-3-(1-thieno[3,2-d]pyrimidin-4-yl-piperidin-4-yl)-urea 4-Phenoxyphenyl isocyanate (35 mg, 170 μmol) was added to a solution of 1-thieno[3,2-d]pyrimidin-4-yl-piperidin-4-ylamine (35 mg, 150 μmol) (Example 20b) in DCM (300 μL). The solution was stirred at rt overnight, at which point it became a slurry. The reaction was then partitioned with DCM (2 mL) and 2.0M K2CO3 (2 mL), the aqueous layer was extracted with 9:1 DCM/MeOH (2*2 mL), and the combined organic layers were filtered. The clear filtrate was dried (Na2SO4), concentrated, and purified by C18 HPLC followed by a bicarbonate solid phase extraction cartridge to afford the title compound (46.6 mg, 70%). 1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 7.72 (d, 1H), 7.42 (d, 1H), 7.33 (m, 2H), 7.22 (m, 2H), 7.10 (m, 1H), 6.97 (m, 4H), 6.19 (br s, 1H), 4.76 (m, 2H), 4.54 (d, 1H), 4.08 (m, 1H), 3.30 (m, 2H), 2.16 (m, 2H), 1.45 (m, 2H). LC/MS (ESI): calcd mass 445.2, found 446.1 (MH)+.

Reference： [1]Current Patent Assignee: JOHNSON & JOHNSON INC - US2006/281768, 2006, A1 Location in patent: Page/Page column 30
[2]Current Patent Assignee: JOHNSON & JOHNSON INC - US2006/281769, 2006, A1 Location in patent: Page/Page column 45

40
[ 916730-87-5 ]
[ 59377-19-4 ]
4-(6,7-Dimethoxy-quinazolin-4-yl)-piperidine-1-carboxylic acid (4-phenoxy-phenyl)-amide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
44%	In N,N-dimethyl-formamide at 20℃;	47 EXAMPLE 47; 4-(6,7-Dimethoxy-quinazolin-4-yl)-piperidine-1-carboxylic acid (4-phenoxy-phenyl)-amide; A solution of 6,7-dimethoxy-4-piperidin-4-yl-quinazoline (20 mg, 0.0733 mmol), as prepared in Example 1d, in DMF (1 mL) was treated with 4-phenoxyphenyl isocyanate (23 mg, 0.109 mmol) at RT overnight. The reaction was then partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo. Purification by prep tlc (1:9 MeOH/DCM) afforded the title compound as a brown solid (15.7 mg, 44%). 1H NMR (300 MHz, CDCl3) δ 9.10 (s, 1H), 7.48 (m, 1H), 7.33 (m, 5H), 7.07 (m, 1H), 6.99 (m, 4H), 6.41 (br s, NH), 4.32-4.27 (m, 2H), 4.09 (s, 6H), 3.63 (m, 1H), 3.20 (m, 2H), 2.17 (m, 2H), 2.03-1.99 (m, 2H); LC/MS (ESI) calcd mass 484.2, found 485.3 [M+1]+.

Reference： [1]Current Patent Assignee: JOHNSON & JOHNSON INC - US2006/281772, 2006, A1 Location in patent: Page/Page column 74

41
C₁₇H₂₈N₄O₄ [ No CAS ]
[ 59377-19-4 ]
C₃₀H₃₇N₅O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: C₁₇H₂₈N₄O₄; p-phenoxyphenylisocyanate With triethylamine In dichloromethane at 20℃; Stage #2: With tris(2-aminoethyl)amine polystyrene HL In dichloromethane at 20℃; for 3h;	A1.b Intermediate 1 (0.0010 mol) and triethylamine (0.0020 mol) were dissolved in DCM (5 ml), l-isocyanato-4-phenoxy- benzene (0.0015 mol) was added). The reaction mixture was shaken overnight at room temperature. Then, Tris-(2-aminoethyl)-amine polystyrene HL (Novabiochem; Cat. No. 01-64-0170) (0.0016 mol) was added. The reaction mixture was shaken for 3 hours at room temperature, then filtered and the filtrate was concentrated, yielding intermediate 2. EPO c)._

Reference： [1]Current Patent Assignee: JOHNSON & JOHNSON INC - WO2006/136553, 2006, A1 Location in patent: Page/Page column 32

42
[ 59377-19-4 ]
[ 98063-21-9 ]
[ 1059702-77-0 ]

Yield	Reaction Conditions	Operation in experiment
16%	With N-ethyl-N,N-diisopropylamine In methanol for 18h;	1.S8 To a solution of (7?)-aminocarnitine (22 mg, 0.14 mmol) and diisopropylethylamine (71 uL, 0.41 mmol) in MeOH (2 mL) was added 1- isocyanato-4-octylbenzene (63 uL, 0.27 mmol) and the reaction stirred for 18h. The MeOH was removed in vacuo and the residue stirred with 1 : 1 ether/EtOAc. Impurities dissolved into the ether/EtOAc which were discarded and the remaining material taken up into 90:10 CH2Cl2/Me0H and then loaded onto a short SiOH plug. The title compound was eluted by increasing MeOH content in 10% steps to 60%. The compound was then taken up into 90:10 CH2Cl2/Me0H and filtered through a plug of celite which gave after drying the title compound as a white powder (9 mg, 17%). 1H NMR (400 MHz, CD3OD) δ 7.27 (d, 2H, J = 8.4 Hz), 7.09 (d, 2H, J = 8.4 Hz), 4.73-4.71 (m, IH), 3.78-3.53 (m, 2H), 3.25 (s, 9H), 2.75-2.72 (m, 2H), 2.55 (t, 2H, J = 8.0 Hz ), 1.60-1.29 (m, 12H), 0.90 (t, 3H, J = 6.8 Hz); MS ESI 392.3 [M + H]+, calcd for [C22H37N3O3 + H]+ 392.55.

Reference： [1]Current Patent Assignee: UNIVERSITY HEALTH NETWORK - WO2008/109991, 2008, A1 Location in patent: Page/Page column 86-87

43
[ 59377-19-4 ]
[ 84758-81-6 ]
C₂₁H₂₆N₂O₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In tetrahydrofuran; at 20℃; for 2h;	1) Preparation of 5,5-dimethyl-3-(4-phenoxyphenyl)imidazolidine-2,4-dione (49.1) Compound 49.1 can be prepared by process "A". To this end, 7.8 g of <strong>[84758-81-6]tert-butyl 2-amino-2-methylpropionate hydrochloride</strong> were suspended at room temperature in 100 ml of dry tetrahydrofuran, and admixed with 8.9 g of 4-phenoxyphenyl isocyanate and 8.4 ml of triethylamine, and the mixture was stirred at room temperature for 2 h. Thereafter, 20 ml of concentrated hydrochloric acid were added and the mixture was stirred under reflux for a further 2 h. The cooled reaction mixture was admixed with water and ethyl acetate; the organic phase was washed with saturated sodium hydrogencarbonate solution and then with concentrated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was stirred with diisopropyl ether, filtered off with suction, washed with more diisopropyl ether and dried. 49.1 was obtained with the melting point of 165 C. in a yield of 97%. Molecular weight 296.11 (C17H16N2O3); retention time Rt=1.95 min.; MS (ESI): 297.42 (MH+).

Reference： [1]Patent: US2009/215728,2009,A1 .Location in patent: Page/Page column 47

44
[ 59377-19-4 ]
[ 758698-76-9 ]
(S)-N-(2-diisopropylamino-ethyl)-2-[3-(4-phenoxy-phenyl)-ureido]-3-phenyl-propionamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
55%	Stage #1: [(S)-1-(2-diisopropylamino-ethyl-carbamoyl)-2-phenyl-ethyl]-carbamic acid tert-butyl ester With hydrogenchloride In 1,4-dioxane; dichloromethane at 20℃; for 3h; Stage #2: p-phenoxyphenylisocyanate With triethylamine In dichloromethane at 0 - 20℃; for 2h;	7 EXAMPLE 7 (S)-N- (2-Diisopropylamino-ethyl)-2- [3- (4-phenoxy-phenyl)-ureido]-3-phenyl- propionamide. To a solution of [(S)-1-(2-diisopropylamino-ethylcarbamoyl)-2-phenyl-ethyl]- carbamic acid tert-butyl ester (Example 3, step B) (0.1 g, 0.258 mmol) in CH2CI2 (3 mL), a 4 M solution of HCI in dioxane (0.64 mL, 2.56 mmol) was added, and the mixture was stirred for 3 h at rt. The solvents were removed, the residue was treated with CH2CI2, and the solvent was removed again. The crude product was dissolved in CH2CI2 (3 mL), and triethylamine (0.037 g, 0.365 mmol) was added at 0 °C followed by 4-phenoxyphenylisocyanate (0.059 g, 0.28 mmol). The mixture was warmed to rt over a period of 2 h and was then diluted with EtOAc (100 mL). The organic layer was washed with saturated NaHCO3 (25 mL) and brine (25 mL), and dried (Na2SO4). The solvent was removed, and the residue was purified by flash column chromatography using 0-20% MeOH (1% NH40H)/CH2CI2 to afford 0.07 g (55%) of the desired product. MS (electrospray) : mass calculated for C3oH38N403, 502.29 ; m/zfound, 503.3 [M+H] +.'H NMR (400 MHz, CD30D) : 7.3-7. 19 (m, 9H), 7.04 (m, 1 H), 6.91-6. 85 (m, 4H), 4.47 (t, J = 7.4 Hz, 1 H), 3.19-2. 95 (m, 6H), 2.42 (br s, 2H), 1.02 (d, J= 6.4 Hz, 12H).

Reference： [1]Current Patent Assignee: JOHNSON & JOHNSON INC - WO2005/44810, 2005, A1 Location in patent: Page/Page column 49

45
[ 59377-19-4 ]
[ 139545-04-3 ]
[ 760214-57-1 ]

Yield	Reaction Conditions	Operation in experiment
50%	Stage #1: [L-(trans)]-4-[(t-butoxycarbonyl)amino]-5-phenyl-2-pentenoic acid With hydrogenchloride In 1,4-dioxane; dichloromethane at 20℃; for 0.25h; Stage #2: p-phenoxyphenylisocyanate With triethylamine In tetrahydrofuran at 0 - 20℃; for 3.5h;	18.A EXAMPLE 18 (E)-(S)-4-[3-(4-Phenoxy-phenyl)-ureido]-5-phenyl-pent-2-enoic acid (2- methylamino-ethyl)-amide. A. (E)- (S)-4-f3- (4-Phenoxy-phenvl)-ureidol-5-phenyl-pent-2-enoic acid. To a solution of (E)-(S)-4-tert-butoxycarbonylamino-5-phenyl-pent-2-enoic acid (Example 11, step A) (2.12 g, 7.26 mmol) in CH2CI2 (73 mL) was added 4 M HCI in 1,4-dioxane (25 mL), and the resulting solution was stirred at rt for 15 min. The solvent was removed. To a solution of the resulting residue and TEA (0.74 g, 7.26 mmol) in THF (73 mL) cooled to 0 °C, was added 4-phenoxy phenyl isocyanate (1.53 g, 7.26 mmol), and the mixture was stirred for 30 min. The solution was brought to rt and was stirred for an additional 3 h. The solvent was removed, and the resulting yellow oil was purified by column chromatography on silica gel using a gradient of 0-35% (MeOH (10% acetic acid)/CH2CI2). The purified product was recrystallized from CH2CI2 and was washed with hexanes to afford 1.45 g (50%) of the desired product as a grey solid. Rf = 0. 47 (5% MeOH (1% NH40H)/CH2CI2). MS (electrospray) : mass calculated for C24H22N204, 402.16 ; ? T/ ? found, 403.1 [M+H]+, 425.1 [M+Na] +, 827.3 [2M+Na] +. 1H NMR (400 MHz, DMSO-d6) : 12.34 (brs, 1H), 8.51 (s, 1H), 7.40-7. 20 (m, 9H), 7.08-7. 05 (m, 1 H), 6.93-6. 91 (m, 4H), 6.86 (d, J = 5.0 Hz, 1 H), 6.35 (d, J = 8.5 Hz, 1 H), 5.77 (dd, J = 15.6, 1.6 Hz, 1 H), 4.70-4. 61 (m, 1 H), 2.93 (dd, J= 13.7, 6.1 Hz, 1H), 2.84 (dd, J= 13.7, 7.9 Hz, 1H).

Reference： [1]Current Patent Assignee: JOHNSON & JOHNSON INC - WO2005/44810, 2005, A1 Location in patent: Page/Page column 64-65

46
[ 150544-04-0 ]
[ 59377-19-4 ]
[ 1236291-34-1 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 4674 - 4686

47
[ 123-30-8 ]
[ 59377-19-4 ]
[ 1380411-49-3 ]

Yield	Reaction Conditions	Operation in experiment
93%	In acetonitrile	4.2.4 General procedure for preparation of diaryl urea derivatives (8a-h) and 10 General procedure: To a stirred solution of isocyanate derivatives 6a-h (13mmol) in acetonitrile (100mL), was added para-amino-phenol 7 (13mmol, 1.41gr) or benzene 1,4- diamine 9(13mmol, 1.40gr) [38]. The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC (DCM: methanol=9:1). The precipitate was filtered, washed with acetonitrile, and dried to afford compounds 8a-g and 10.
88%	In acetonitrile at 20℃;
	In acetonitrile at 20℃; Inert atmosphere;	General procedure: 4-Aminophenol 1 (1 equiv.) was added to a solution of isocyanate (1 equiv.) in 15-20 ml of acetonitrile. The mixture was stirred at room temperature until the complete formation of the product (TLC monitoring).

Reference： [1]Azimian, Fereshteh; Dastmalchi, Siavoush; Hamzeh-Mivehroud, Maryam; Hemmati, Salar; Shahbazi Mojarrad, Javid [European Journal of Medicinal Chemistry, 2020, vol. 201]
[2]Location in patent: experimental part Gieling, Roben G.; Babur, Muhammad; Mamnani, Lupti; Burrows, Natalie; Telfer, Brian A.; Carta, Fabrizio; Winum, Jean-Yves; Scozzafava, Andrea; Supuran, Claudiu T.; Williams, Kaye J. [Journal of Medicinal Chemistry, 2012, vol. 55, # 11, p. 5591 - 5600]
[3]Winum, Jean-Yves; Carta, Fabrizio; Ward, Carol; Mullen, Peter; Harrison, David; Langdon, Simon P.; Cecchi, Alessandro; Scozzafava, Andrea; Kunkler, Ian; Supuran, Claudiu T. [Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 14, p. 4681 - 4685]

48
[ 59377-19-4 ]
4'-Formylaminobiphenyl ether [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
94%	With zirconocene dichloride; lithium tri-t-butoxyaluminum hydride In tetrahydrofuran; 2-methyltetrahydrofuran at 0 - 20℃; for 1h; Inert atmosphere; chemoselective reaction;

Reference： [1]Pace, Vittorio; De La Vega-Hernández, Karen; Urban, Ernst; Langer, Thierry [Organic Letters, 2016, vol. 18, # 11, p. 2750 - 2753]

49
[ 59377-19-4 ]
methyl α-amino-1-piperidinepropanoate dihydrochloride [ No CAS ]
3-(4-phenoxyphenyl)-5-(piperidin-1-ylmethyl)imidazolidine-2,4-dione hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
42%	Stage #1: p-phenoxyphenylisocyanate; methyl α-amino-1-piperidinepropanoate dihydrochloride With triethylamine In dichloromethane at 20℃; for 24h; Stage #2: With hydrogenchloride In water at 20℃; for 72h;	3-(4-Phenoxyphenyl)-5-(piperidin-1-ylmethyl)imidazolidine-2,4-dione hydrochloride (3d) A solution of 1-isocyanato-4-phenoxybenzene (407.6 mg, 1.93 mmol) in CH2Cl2 was added to a solution ofmethyl 2-amino-3-(piperidin-1-yl)propanoate dihydrochloride (500.3 mg, 1.93 mmol) and Et3N (535.1 µL,3.86 mmol) in CH2Cl2. The mixture was stirred at rt for 1 day and washed with water and brine, driedover Na2SO4, and concentrated in vacuo. Concentrated HCl (5 mL) was added to this mixture and themixture was allowed to stand for 3 days at rt and then the solvent was removed under reduced pressure. EtOH was added to this mixture and the precipitated material was filtered to give the desired compound 3d (327.0 mg, 42% yield) as a white solid. Mp 178-185 °C; IR (KBr) 3454 (NH), 1778 (C=O), 1704 cm-1(C=O); FAB-MS (positive) m/z 366 (M+H)+. HRMS (FAB) Calcd for C21H24N3O3+: m/z 366.1812(M+H)+. Found: 366.1826; 1H-NMR (DMSO-d6) δ 1.30-2.00 (6H, m, Pip H-3 ×2, H-4 ×2, H-5 ×2),2.70-3.90 (6H, m, Pip H-2 ×2, H-6 ×2, CH2-Pip), 4.88-4.98 (1H, m, Hyd H-5), 7.02-7.15 (4H, m, Ar),7.15-7.22 (1H, m, Ar), 7.40-7.50 (2H, m, Ar), 7.40-7.50 (2H, m, Ar), 8.83 (1H, s, Hyd H-1), 10.77 (1H, s,NH+); 13C-NMR (DMSO-d6) δ 21.1 (Pip C-4), 22.3 (Pip C-3, C-5), 22.3 (Pip C-3, C-5), 52.1 (Pip C-2 orC-6), 52.3 (Hyd C-5), 53.6 (Pip C-2 or C-6), 58.1 (CH2-Pip), 118.4, 119.0, 123.9, 128.4, 130.1 (Ar C-2,C-6 or C-3, C-5 in C6H4 or Ar C-2, C-6 or C-3, C-5 or C-4 in Ph), 126.8 (Ar C-1 in C6H4), 155.2 (HydC-2), 156.1 (Ar C-4 in C6H4 or Ar C-1 in Ph), 156.3 (Ar C-4 in C6H4 or Ar C-1 in Ph), 170.2 (Hyd C-4).Anal. Calcd for C21H23N3O3 • HCl: C, 62.76; H, 6.02; N, 10.46. Found: C, 62.56; H, 5.97; N, 10.41.

Reference： [1]Furutachi, Makoto; Fujisaki, Fumiko; Tsuru, Reika; Ejima, Ayumi; Gondo, Toshiaki; Goto, Saho; Ito, Miki; Nakamura, Maki; Aki, Hatsumi; Kashige, Nobuhiro; Miake, Fumio; Sumoto, Kunihiro [Heterocycles, 2016, vol. 92, # 6, p. 1111 - 1120]

50
(S)-1-(3-chloropyridin-2-yl)-N-(1-hydroxypropan-2-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide [ No CAS ]
[ 59377-19-4 ]
(S)-2-(1-(3-chloropyridin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamido)propyl(4-phenoxyphenyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
89%	In tetrahydrofuran at 20℃;	General Procedure for the Preparation ofTitleCompounds5a-5r General procedure: A 100 mL round bottom was charged with(S)-1-(3-chloropyridin-2-yl)-N-(1-hydroxypropan-2-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide(1mmol) with various substitutedisocyanatobenzenes(1mmol) in THF (10 mL). The mixture was stirred at room temperature for overnight. The target compounds were filtered and crude solids were recrystallized from ethanol to give the title compounds 5.

Reference： [1]Liu, Xing-Hai; Zhao, Wen; Shen, Zhong-Hua; Xing, Jia-Hua; Yuan, Jing; Yang, Guo; Xu, Tian-Ming; Peng, Wei-Li [Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 15, p. 3626 - 3628]

51
(S)-3-(difluoromethyl)-N-(1-hydroxypropan-2-yl)-1-methyl-1H-pyrazole-4-carboxamide [ No CAS ]
[ 59377-19-4 ]
(S)-2-(3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamido)propyl (4-phenoxyphenyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
83%	In tetrahydrofuran at 20℃;	22 2.2.6. Preparation of compounds 6-1~6-36 General procedure: A 100 mL round bottom was charged with substituted N-(2-hydroxyethyl)-1-methyl-3-(difluoromethyl)-1H-pyrazole-4-carboxamide (1 mmol) with various substituted isocyanatobenzenes(1 mmol) in THF (10 mL). The mixture was stirredat room temperature for overnight. The target compounds werefiltered and crude solids were recrystallized from ethanol to givethe title compounds 6. All the compounds were synthesized accordingto this procedure (Scheme 1).

Reference： [1]Liu, Xing-Hai; Zhao, Wen; Shen, Zhong-Hua; Xing, Jia-Hua; Xu, Tian-Ming; Peng, Wei-Li [European Journal of Medicinal Chemistry, 2017, vol. 125, p. 881 - 889]

52
N‐(3‐aminobenzyl)‐6,7‐difluoroquinoxalin‐2‐ amine [ No CAS ]
[ 59377-19-4 ]
1-(3-(((6,7-difluoroquinoxalin-2-yl)amino)methyl)phenyl)-3-(4-phenoxyphenyl)urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine In 1,2-dichloro-ethane at 20℃;	5 Preparation of compound e [C28H21F2N5O2,1-(3-(((6,7-difluoromethyl-2-yl)amino)methyl)phenyl]-3-(4-phenoxyphenyl)urea] : Dissolve 1 mmol of N-(3-aminobenzyl)-2-amine-6,7-difluoroquinoxaline in 1,2-dichloroethane.1 mmol of triethylamine was added dropwise.Then add 1 mmol of 4-phenoxyphenyl isocyanate,The mixture reacts at room temperature overnight (TLC monitoring reaction),After the reaction is completed, flash silica gel column chromatography (petroleum ether:ethyl acetate=2:1),Purified 1-(3-(((6,7-difluoromethyl-2-yl)amino)methyl)phenyl)-3-(4-phenoxyphenyl)urea was obtained.

Reference： [1]Current Patent Assignee: GUANGXI NORMAL UNIVERSITY - CN107935944, 2018, A Location in patent: Paragraph 0077; 0078; 0082; 0083-0087

53
[ 59377-19-4 ]
[ 98-32-8 ]
4-hydroxy-3-(3-(4-phenoxyphenyl)ureido)benzenesulfonamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 6328 - 6338

54
1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-3-(difluoromethyl)-N-(1-hydroxypropan-2-yl)-1H-pyrazole-4-carboxamide [ No CAS ]
[ 59377-19-4 ]
2-(1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-3-(difluoromethyl)-1H-pyrazole-4-carboxamido)propyl (4-phenoxyphenyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
85%	In tetrahydrofuran at 20℃;	2.2. Synthesis Target Compounds 5a-5u General procedure: To a solution of intermediate 4 (0.43g, 1 mmol) in THF (5 mL), substituted isocyanatobenzenes (1 mmol) in THF (5 mL) was dropwisly. The mixture was stirred at room temperature overnight. The final compound was given in solid and recrystallized from ethanol.

Reference： [1]Cheng, Long; Zhao, Wen; Shen, Zhong-Hua; Xu, Tian-Ming; Wu, Hong-Ke; Peng, Wei-Li; Liu, Xing-Hai [Letters in drug design and discovery, 2018, vol. 16, # 1, p. 29 - 35]

55
(E)-2-(3-hydroxybenzylidene)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one [ No CAS ]
[ 59377-19-4 ]
(E)-3-[(5,6-dimethoxy-1-oxo-1,3-dihydro-2H-inden-2-ylidene)methyl]phenyl(4-phenoxyphenyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
48%	With triethylamine In dichloromethane Reflux;	4.2.2. ( E )-3-[(5,6-dimethoxy-1-oxo-1,3-dihydro-2H-inden-2-ylidene) methyl] phenyl (3/4-substituted phenyl) carbamate (3a-i) The indanone-carbamate derivatives ( 3a-i ) were synthesized from adding the phenyl isocyanate derivative (1 mmol) to a sus- pension of 2a (1 mmol) and triethyl amine (0.5 ml) in dry CH 2 Cl 2 (40 ml). After overnight reflux and TLC monitoring, the mixture was cooled to room temperature. The solution was washed with water and then the organic phase was dried with sodium sulfate, filtered and the solvent was removed with a rotary vacuum evap- orator. The crude product was purified by recrystallized from 2- butanone (methyl ethyl ketone) to afford final compounds ( 3a-i ) in different yields.

Reference： [1]Ayazgök, Beyza; Dastmalchi, Siavoush; Hamzeh-Mivehroud, Maryam; Hemmati, Salar; Notash, Behrouz; Shahbazi Mojarrad, Javid; Shahrivar-Gargari, Mohammad; Tüylü Küçükkılınç, Tuba [Journal of Molecular Structure, 2021, vol. 1229]

56
2-(3-hydroxybenzyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one [ No CAS ]
[ 59377-19-4 ]
3-[(5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl)methyl]phenyl(4-phenoxyphenyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
44%	With triethylamine In dichloromethane at 40℃;	4.2.4. 3-[(5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl) methyl] phenyl (3/4- substituted phenyl) carbamate (4a-i) General procedure: To a mixture of 2b (1 mmol) and triethyl amine (0.5 ml) in 40 ml dry CH 2 Cl 2 , proper phenyl isocyanate (1 mmol) was added and the mixture was refluxed at 40 °C for overnight. After TLC checking, the solution was washed with water and then, the organic phase was dried over Na 2 SO 4 and the solvent was removed with rotary vacuum evaporator. The resulted solid was purified by recrystal- lization from ethanol or ethyl acetate to produce final appropriate carbamate target ( 4a-i ).

Reference： [1]Ayazgök, Beyza; Dastmalchi, Siavoush; Hamzeh-Mivehroud, Maryam; Hemmati, Salar; Notash, Behrouz; Shahbazi Mojarrad, Javid; Shahrivar-Gargari, Mohammad; Tüylü Küçükkılınç, Tuba [Journal of Molecular Structure, 2021, vol. 1229]

57
2-(N-(4-sulfamoylphenyl)sulfamoyl)ethanamine hydrochloride [ No CAS ]
[ 59377-19-4 ]
4-(2-(3-(4-phenoxyphenyl)ureido)ethylsulfonamido)benzenesulfon amide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
55%	With N-ethyl-N,N-diisopropylamine In acetonitrile at 65℃; Inert atmosphere;	4.2 General procedure for the synthesis of compounds 1-29 [14] General procedure: 2-(N-(4-Sulfamoylphenyl)sulfamoyl)ethanamine HCl salt was reacted with commercially available isocyanates (1.0 equiv.) and diisopropylethyl amine (DIPEA, 2.0 equiv.) dry acetonitrile (ACN, 8.0ml) at 65°C under a nitrogen atmosphere. After consumption of the starting material (TLC monitoring) the solvent was evaporated under vacuum and the crude material was purified by silica gel column chromatography eluting with appropriate solvents to afford the title compounds 1-29.

Reference： [1]Akgul, Ozlem; Singh, Srishti; Andring, Jacob T.; McKenna, Robert; Selleri, Silvia; Carta, Fabrizio; Angeli, Andrea; Supuran, Claudiu T. [European Journal of Medicinal Chemistry, 2021, vol. 212]

58
[ 4403-70-7 ]
[ 59377-19-4 ]
[ 143007-15-2 ]
1-(3-(((6,7-difluoroquinoxalin-2-yl)amino)methyl)phenyl)-3-(4-phenoxyphenyl)urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
83%	Stage #1: m-aminobenzylamine; 2-chloro-6,7-difluoroquinoxaline With triethylamine In isopropyl alcohol at 120℃; for 6h; Stage #2: p-phenoxyphenylisocyanate With triethylamine In 1,2-dichloro-ethane at 20℃;	Synthesis procedure General procedure: One mmol of 2-chloroquinoxaline and 1.2 mmolof 3-aminobenzylamine were added to an isopropanolsolution, and then 1.2 mmol of triethylamine was addeddropwise to this solution. The mixture was refluxed at120 °C for 6 h until the reaction was completed (monitoredby TLC).After removing the solvent under reduced pressure, theresidue was dissolved in 1,2-dichloroethane solution, then1 mmol of triethylamine was added dropwise, followed by1 mmol of isothiocyanatobenzene or isocyanate. The mixturewas reacted at room temperature overnight, and thereaction was monitored by TLC. After completion of thereaction, the reaction mixture was evaporated to dryness invacuo to afford a residue, which was purified by column[petroleum ether/ethyl acetate, 2:1 (v/v)] to obtain targetcompounds.

Reference： [1]Li, Gui-Zhen; Ouyang, Xi-Lin; Mo, Zu-Yu; Gu, Yao; Cao, Xiao-Lin; Yang, Li; Tang, Hai-Tao; Pan, Ying-Ming [Medicinal Chemistry Research, 2021, vol. 30, # 8, p. 1496 - 1511]

59
[ 69906-00-9 ]
[ 551-93-9 ]
[ 59377-19-4 ]
1'-ethyl-3-(4-phenoxyphenyl)-1H,1'H-spiro[quinazoline-4,2'-quinolin]-2(3H)-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65%	With iron(III) chloride In ethanol at 50℃; for 8h; Green chemistry;

Reference： [1]Ma, Yongmin; Pan, Zhentao; Shi, Shuaijun; Wang, Shiliang; Xiao, Xuqiong; Yang, Xuancheng; Zhang, Wangqin [Green Chemistry, 2021, vol. 23, # 8, p. 2944 - 2949]

60
[ 1520-21-4 ]
[ 59377-19-4 ]
1-(4-vinylphenyl)-3-(4-phenoxyphenyl)urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
55%	In tetrahydrofuran at 20℃; Inert atmosphere;	2.2 Synthesis of the functional monomers 1 - 4. General procedure: The synthesis of compounds 1-3 was carried out using a procedure similar to that reported by Hall et al. [24]. In the case of monomer 4, a similar strategy was employed. In general, the corresponding isocyanate (2.5mmol; see below) was added to a 10mL solution of 4-vinylaniline (0.30g, 2.5mmol) in THF under nitrogen atmosphere, and the solution was stirred at room temperature for 24 to 48h. The solvent was evaporated under reduced pressure and the crude reaction product was purified according to the case (see below).

Reference： [1]Quiñone, Delfina; Belluzzi, Marcelo; Torres, Julia; Brovetto, Margarita; Veiga, Nicolás [Polyhedron, 2022, vol. 225]

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

CAS No. :	59377-19-4	MDL No. :	MFCD00013876
Formula :	C₁₃H₉NO₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	PNBUGOFIKAHZRW-UHFFFAOYSA-N
M.W :	211.22	Pubchem ID :	2734896
Synonyms :

Signal Word:	Danger	Class:	6.1
Precautionary Statements:	P261-P305+P351+P338-P311	UN#:	2206
Hazard Statements:	H302-H315-H319-H331-H334-H335	Packing Group:	Ⅲ
GHS Pictogram:

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

[ CAS No. 59377-19-4 ] {[proInfo.proName]}

Quality Control of [ 59377-19-4 ]

Related Doc. of [ 59377-19-4 ]

Product Details of [ 59377-19-4 ]

Safety of [ 59377-19-4 ]

Application In Synthesis of [ 59377-19-4 ]

[ 59377-19-4 ] Synthesis Path-Downstream 1~60

Related Functional Groups of
[ 59377-19-4 ]

Aryls

Ethers

Isocyanates and Isothiocyanates

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

[ CAS No. 59377-19-4 ] {[proInfo.proName]}

Quality Control of [ 59377-19-4 ]

Related Doc. of [ 59377-19-4 ]

Product Details of [ 59377-19-4 ]

Safety of [ 59377-19-4 ]

Application In Synthesis of [ 59377-19-4 ]

[ 59377-19-4 ] Synthesis Path-Downstream 1~60

Related Functional Groups of [ 59377-19-4 ]

Aryls

Ethers

Isocyanates and Isothiocyanates

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 59377-19-4 ]